A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation. - Wikidata - awgldk - TriplyDB

A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation.

A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation.

http://www.wikidata.org/entity/Q35286303

about

New and emerging therapies for the treatment of irritable bowel syndrome: an update for gastroenterologists Irritable bowel syndrome: new insights into symptom mechanisms and advances in treatment Recent Updates on the Treatment of Constipation Non-systemic drugs: a critical review Brain-gut axis: from basic understanding to treatment of IBS and related disorders Current developments in pharmacological therapeutics for chronic constipation Treatment for constipation: new and old pharmacological strategies Elobixibat and its potential role in chronic idiopathic constipation Emerging Pharmacologic Therapies for Constipation-predominant Irritable Bowel Syndrome and Chronic Constipation.Understanding and treating refractory constipation.Luminally Acting Agents for Constipation Treatment: A Review Based on Literatures and Patents.Constipation-predominant irritable bowel syndrome: a review of current and emerging drug therapies.American Gastroenterological Association technical review on constipation.Sodium-dependent bile salt transporters of the SLC10A transporter family: more than solute transporters.Treatment of Chronic Constipation: Prescription Medications and Surgical Therapies.Specific inhibition of bile acid transport alters plasma lipids and GLP-1 Inhibition of ileal bile acid transporter: An emerging therapeutic strategy for chronic idiopathic constipation.Chronic constipation in the elderly: a primer for the gastroenterologist Advancing treatment options for chronic idiopathic constipation.Therapeutic targeting of bile acids Early investigational therapeutics for gastrointestinal motility disorders: from animal studies to Phase II trials.New and Emerging Treatment Options for Irritable Bowel Syndrome.Evolution of substrate specificity for the bile salt transporter ASBT (SLC10A2).The solute carrier family 10 (SLC10): beyond bile acid transport Chronic Constipation and Constipation-Predominant IBS: Separate and Distinct Disorders or a Spectrum of Disease?Pharmacological agents currently in clinical trials for disorders in neurogastroenterology.Novel pharmacological therapies for management of chronic constipation.c-Fos mediates repression of the apical sodium-dependent bile acid transporter by fibroblast growth factor-19 in mice Pharmacology of the new treatments for lower gastrointestinal motility disorders and irritable bowel syndrome.New treatment options for chronic constipation: mechanisms, efficacy and safety.Evolving molecular targets in the treatment of nonmalignant gastrointestinal diseases.Agents that act luminally to treat diarrhoea and constipation.Elobixibat for the treatment of constipation.Pharmacokinetic and pharmacodynamic considerations for the current chronic constipation treatments.Emerging treatments for chronic constipation.Linaclotide: a novel compound for the treatment of irritable bowel syndrome with constipation.New pharmacological treatment options for chronic constipation.The role of bile acids in functional GI disorders.Phase II drugs under clinical investigation for the treatment of chronic constipation.American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation.

P2860

Q26748617-299774B5-8CB8-4050-9D36-931959DD0992 Q26751193-12072339-F36A-41E3-AA1E-753A474F9E92 Q26820242-6040D29E-3FDD-40DE-82AD-7F4CC25C0BE2 Q26863371-82A3360A-66D3-473A-BF9D-ABF77D2F9FB3 Q27024801-C1524D5B-0777-4F18-9C0B-93BABDDDD831 Q27025474-DC089E44-65D9-4237-8C46-AC82486E7D23 Q27027346-8F00B713-5719-40CE-A34C-481B39CE96C9 Q28244603-00639B5B-68FE-4839-9357-1EC9A2D7C5BF Q33586854-7B76A180-EBCA-4F05-BFA7-94F8945C23BB Q33621273-DCCDD055-629B-4A4A-996F-BE64840EF0BB Q33854983-240B6873-9B90-4D10-8E52-62EC2225F624 Q33958710-1864C0DC-A34F-42ED-A0A7-34A7BD1DE1C1 Q34319119-CA2A44CB-D412-4766-9FC9-D34401BD2A77 Q34382931-C56AEB4C-44E3-4ED9-8E01-35517416678B Q34522966-02821975-9A89-4D1C-8415-A4C23BAF30F8 Q35703890-EB431066-9BD7-4ECB-8D5E-FDFA48EA575C Q35783889-A66933B2-9610-4B91-9C86-8442AC8200B3 Q35807577-4F0FDA9E-D9CC-48BC-A9AE-CD07FAA753C1 Q35858864-D649DB24-C273-441D-A11C-A7EC71357E94 Q35958534-AC057C6B-A525-4207-B0F7-42C3D48DD4A9 Q36082843-0D9E484F-3600-465B-8D53-38337A54EFCD Q36180769-197B5E9E-B6EE-443A-B4A2-B8C726EB0B26 Q36520337-596987CD-0483-4350-9F6E-08A9CEA83E0E Q36700386-AFA8F1AB-90A7-4B64-B09C-2FE679BDDFDF Q36916631-5CE37480-0679-4127-8054-1ECFA4D428BA Q37200907-C19C5961-9F6D-4436-83B1-76166CEDD361 Q37394824-7D705C35-093C-4112-B293-93EDC7F3F70B Q37575666-9C59E884-C928-4B42-92B8-E3916CA132B1 Q37954521-2E777AD9-5CE2-45CA-A411-7ACC0D88B0E7 Q37960501-B349D03A-0F2D-4FA6-B1F1-7C30C54A6CEC Q38029235-E1D37FEC-B897-4C44-9B0A-AA888F07BBC4 Q38040321-C9A8390A-C418-41A7-BCE0-1539184B812B Q38065210-766AD9D7-B0AB-4C32-8AE0-3DB6B43FFB8C Q38083079-060A393E-8DFA-4D30-A651-A06BC8CB74E1 Q38129960-551D6F59-B0D8-4992-A1E8-BCD02F0F45F8 Q38134412-918C4F7A-37FD-4082-A47D-B7AB1EFCE61A Q38198743-7BA38817-DD60-4599-BA09-944074ECCE32 Q38217671-E262C3A5-F99A-4104-8397-CCD2231EBE21 Q38222819-441ECFD2-FE0E-47CF-B888-6432D2673317 Q38236812-9EB298DC-87D3-4B0C-8AB6-74A285EAB72E

P2860

A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation.

http://www.wikidata.org/entity/Q35286303

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

A randomized placebo-controlle ...... ronic idiopathic constipation.

@ast

A randomized placebo-controlle ...... ronic idiopathic constipation.

@en

type

label

A randomized placebo-controlle ...... ronic idiopathic constipation.

@ast

A randomized placebo-controlle ...... ronic idiopathic constipation.

@en

prefLabel

A randomized placebo-controlle ...... ronic idiopathic constipation.

@ast

A randomized placebo-controlle ...... ronic idiopathic constipation.

@en

P1433

Q35286303-BB0C191B-9220-407C-BDC5-A80ED5271429

P1476

Q35286303-98DB657F-2A91-4379-9677-1FA16FB00354

P2093

Q35286303-695F4363-270E-44B5-B886-CE62004239E8

Q35286303-9206D3B8-409A-41BC-8881-CA0BAB7FFA9A

Q35286303-954860D6-1C4B-4C97-AA2E-2C0D17E4D69B

Q35286303-C5BC7326-3834-4EE7-9BB6-345BFE9F0A9F

P2860

Q35286303-06A51316-8787-4E2E-BB33-F4BB80C29389

Q35286303-0F127713-224E-401C-8017-FD82C21DD64B

Q35286303-11C17847-CE28-4677-AC73-5AE4F09BD422

Q35286303-151ED1CD-2370-453D-86E7-40208B9D33C2

Q35286303-1CFA4CC4-2CD6-4CCB-A6FA-E174E00E0320

Q35286303-283D7BBA-8843-4C63-A417-281D403EB65D

Q35286303-38398D34-7426-4169-BDCA-0D805246C72C

Q35286303-3A9E5D66-A8EE-4D5A-ACAC-6631370B2A1E

Q35286303-3CB14CBF-8086-4644-A3B9-0D56144B8431

Q35286303-3E3DB62D-02A6-4A82-84F7-572534E53A80

P304

Q35286303-58322D93-7A31-4F51-B3D0-071D031843AC

P31

Q35286303-E9239ABD-15E8-4532-B2CF-2BF47F9743D6

P356

Q35286303-61037F3E-A6A1-4716-9A96-8F6919653A47

P407

Q35286303-CDA3DBDF-029F-4154-9255-76482A3F1069

P433

Q35286303-09D7032D-77D8-4C22-87FE-5D7B74B7FCCD

P478

Q35286303-2A10EA0B-0C5C-4FF2-85C3-7EFFCD184E06

P50

Q35286303-91C8056C-ABB7-4718-94CF-D1236922AC6A

P577

Q35286303-567066E0-93C5-4C92-B1D0-4AFFBC4A5F49

P5875

Q35286303-5774A0CE-D0D3-44C5-BC94-85AEE282BA35

P698

Q35286303-821C0EFB-15EE-4327-BFC6-058075639A1B

P921

Q35286303-79929560-1BDE-4672-A87C-AE45EF480892

P932

Q35286303-F0FA6478-7B9E-4F34-AC8B-2DDD08DA49AF

P356

P1433

The American Journal of Gastroenterology

P1476

A randomized placebo-controlle ...... ronic idiopathic constipation.

@en

P2093

Hans Graffner

http://www.w3.org/2001/XMLSchema#string

Leif Rikner

http://www.w3.org/2001/XMLSchema#string

Lin Chang

http://www.w3.org/2001/XMLSchema#string

William D Chey

http://www.w3.org/2001/XMLSchema#string

P2860

Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis

Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function

American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]

Functional bowel disorders

Bile acids and lipoprotein metabolism: a renaissance for bile acids in the post-statin era?

American Gastroenterological Association Medical Position Statement: guidelines on constipation.

An epidemiological survey of constipation in canada: definitions, rates, demographics, and predictors of health care seeking.

Cholestyramine treatment of diarrhea associated with ileal resection.

Effect of bile acid on anorectal function in man.

Bile acid synthesis in humans has a rapid diurnal variation that is asynchronous with cholesterol synthesis.

P304

1803-1812

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/AJG.2011.162

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

106

http://www.w3.org/2001/XMLSchema#string

P50

Michael Camilleri

P577

2011-05-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51160411

http://www.w3.org/2001/XMLSchema#string

P698

21606974

http://www.w3.org/2001/XMLSchema#string

P921

P932

3188811

http://www.w3.org/2001/XMLSchema#string